ResearcherUniversity of OttawaActive in the last 2 years

Yvan Guindon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3057-0456; OpenAlex author ID A5043575731. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 2

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

A Nucleoside Analogue Featuring a C3'-Stereogenic All-Carbon Quaternary Center as a Bioenergetic Disruptor of KRAS-Mutated Pancreatic Cancer Cells. Last author DOI 10.1021/acsmedchemlett.5c00378 ↗
Identification of a C3'-nitrile nucleoside analogue inhibitor of pancreatic cancer cell line growth. Last author DOI 10.1016/j.bmcl.2020.126983 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Houda N. Tantawi · 1 shared paper, 2025 · strength 0.20
- Paper A Nucleoside Analogue Featuring a C3'-Stereogenic All-Carbon Quaternary Center as a Bioenergetic Disruptor of KRAS-Muta… DOI 10.1021/acsmedchemlett.5c00378 ↗
Marc-Olivier Labbé · 1 shared paper, 2020 · strength 0.11
- Paper Identification of a C3'-nitrile nucleoside analogue inhibitor of pancreatic cancer cell line growth. DOI 10.1016/j.bmcl.2020.126983 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.